Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 2
Submit an article Journal homepage
416
Views
15
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Phase II study of alemtuzumab–rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes

Olga FrankfurtNorthwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USACorrespondence[email protected]
,
Shuo MaNorthwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
,
Leo GordonNorthwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
,
Jane N. WinterNorthwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
,
Jeanne M. HorowitzNorthwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
,
Alfred RademakerNorthwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
,
Bing Bing WeitnerNorthwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
,
LoAnn C. PetersonNorthwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
,
Jessica K. AltmanNorthwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
,
Martin S. TallmanMemorial Sloan-Kettering Cancer Center, New York, NY, USA
,
Adam PetrichNorthwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
&
Steven T. RosenCity of Hope Comprehensive Cancer Center, Duarte, CA, USA
 show all
Pages 315-323 | Received 12 Aug 2013, Accepted 25 Mar 2014, Published online: 17 Jun 2014

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Anna Korycka-Wołowiec, Dariusz Wołowiec & Tadeusz Robak. (2017) The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. Expert Opinion on Drug Safety 16:2, pages 185-201.
Read now
Maria Chaudhry & Bruce D Cheson. (2015) What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?. Expert Review of Hematology 8:6, pages 733-742.
Read now
Clive S. Zent, Timothy G. Call, Deborah A. Bowen, Michael J. Conte, Betsy R. LaPlant, Thomas E. Witzig, Stephen M. Ansell & George J. Weiner. (2015) Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. Leukemia & Lymphoma 56:8, pages 2373-2378.
Read now
Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2015) Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs 20:3, pages 423-447.
Read now
Christian H. Geisler, Tamar Tadmor & Aaron Polliack. (2015) Treating chronic lymphocytic leukemia with a combination of rituximab and alemtuzumab: a “successful couple,” but are they still relevant together?. Leukemia & Lymphoma 56:2, pages 275-276.
Read now

Articles from other publishers (10)

Fausto Alfredo Rios-Olais & Talal Hilal. (2023) Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice. Current Treatment Options in Oncology 24:8, pages 907-928.
Crossref
Giovanni D’Arena, Alessandro Sgambato, Silvestro Volpe, Giuseppe Coppola, Rachele Amodeo, Virginia Tirino, Fiorella D’Auria, Teodora Statuto, Luciana Valvano, Giuseppe Pietrantuono, Silvia Deaglio, Dimitar Efremov, Luca Laurenti & Antonella Aiello. (2022) Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?. Hematological Oncology 40:5, pages 835-842.
Crossref
Shuo Ma, Steven T. Rosen, Maria Winqvist, Olga Frankfurt, Jane N. Winter, Leo Gordon, Irene Helenowski, Hui Zhang, Jennifer Kreutzer, Sonja Sönnert-Husa, Anders Österborg & Jeanette Lundin. (2022) Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study. Leukemia Research 122, pages 106945.
Crossref
William G. Wierda, Andrew Rawstron, Florence Cymbalista, Xavier Badoux, Davide Rossi, Jennifer R. Brown, Alexander Egle, Virginia Abello, Eduardo Cervera Ceballos, Yair Herishanu, Stephen P. Mulligan, Carsten U. Niemann, Colin P. Diong, Teoman Soysal, Ritsuro Suzuki, Hoa T. T. Tran, Shang-Ju Wu, Carolyn Owen, Stephan Stilgenbauer, Paolo Ghia & Peter Hillmen. (2021) Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia 35:11, pages 3059-3072.
Crossref
Catherine C. Coombs. 2020. Novel Therapeutics for Rare Lymphomas. Novel Therapeutics for Rare Lymphomas 47 67 .
Craig S. Boddy & Shuo Ma. (2018) Frontline Therapy of CLL: Evolving Treatment Paradigm. Current Hematologic Malignancy Reports 13:2, pages 69-77.
Crossref
Hind Rafei & Mohamed A. Kharfan-Dabaja. (2018) Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. Hematology/Oncology and Stem Cell Therapy 11:1, pages 1-12.
Crossref
Linda M. Henricks, Jan H.M. Schellens, Alwin D.R. Huitema & Jos H. Beijnen. (2015) The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treatment Reviews 41:10, pages 859-867.
Crossref
Josephine N Emole, Frederick L Locke & Javier Pinilla-Ibarz. (2015) An update on current and prospective immunotherapies for chronic lymphocytic leukemia. Immunotherapy 7:4, pages 455-466.
Crossref
Ngoc Kim Phan. (2014) Biological therapy: a new age of cancer treatment. Biomedical Research and Therapy 1:2.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.